LAS VEGAS, Dec. 3, 2019 /PRNewswire/ -- JanOne Inc.
(NASDAQ:JAN) a company focused on reducing opioid addiction by
finding treatments for conditions accompanied by pain and bringing
to market drugs and therapies with nonaddictive pain-relieving
properties, announced the hiring of Tony
Giordano, Ph.D. to serve as its Chief Scientific
Officer.
Dr. Giordano is JanOne's new Chief Scientific Officer and
founding scientist. As Chief Scientific Officer, Dr. Giordano will
oversee development of the company's recently announced PAD
treatment, TV1001SR including the phase 2b clinical protocol, manufacturing, and phase
2b clinical trials. In addition to
his role with JanOne, he also serves as Senior Director of Special
Projects in the Innovations Center at the Cleveland Clinic.
"I'm delighted to announce Dr. Giordano's appointment as Chief
Scientific Officer," said Eric Bolling, president of JanOne.
"His knowledge and his experience in the sciences are invaluable in
helping create and advance JanOne's mission. We look forward to his
leadership as we work to develop JanOne's pipeline of drug
treatments to target the cause of pain, or pain itself, and that in
the future may replace opioids currently in medicine cabinets
across America."
"Dr. Giordano will play a key role in the identification of
future clinical candidates as we develop our pipeline, targeting
solutions that can treat an underlying condition and associated
pain without the need for opioids," said Tony Isaac, JanOne's Chief Executive
Officer.
As an experienced researcher and bioscientist, Dr.
Giordano has held senior positions at cutting-edge
biotechnology companies. As President of Sulfagenix, Inc., he
managed the completion of a Phase 1 clinical study, GRAS
affirmation and launch of medical food product. As Chief
Executive Officer of Theravasc, Inc., he managed collaborations and
development of a new drug formulation, TV1001SR, that JanOne
recently licensed, and oversaw and managed the Phase 1 clinical
study and two-Phase 2 studies. He also held senior positions
at Message Pharmaceuticals, Inc., Nucleonics, Inc., and
Alteris, Inc.
"I am honored to be named JanOne's Chief Scientific Officer,"
said Dr. Giordano. "I am fortunate to have the opportunity to
continue my work with TV1001SR and to advance it into Phase
2b for treating PAD with an
additional indication for PAD-associated pain. The potential
down the road to explore how TV1001SR may provide non-addictive
pain relief to patients with various chronic pain conditions will
shape our future research."
Prior to Theravasc, Dr. Giordano had served as an Adjunct
Professor of Biology at Case Western
University, Special Advisor to the Chancellor at LSU Health
Sciences Shreveport and as the Assistant Dean of Research and
Business Development at Louisiana State
University's Health & Sciences Center, where he worked
with faculty to define the commercial potential of their research
and identified and brought in funding through sponsored research
agreements. Additionally, Dr. Giordano served as Director of
Experimental Therapeutics in the Feist-Weiller Cancer Center, and
as Associate Professor in the Departments of Pharmacology and
Biochemistry.
He served as advisor to three biotechnology venture
capital funds, a consultant to the Biomedical Research
Foundation, and was appointed by the Governor of Louisiana to the Innovation Council. Dr.
Giordano has more than 20 issued patents and a number of
pending patent applications and has published more than 50 research
studies. Before beginning his career in biotech, Dr. Giordano was a
senior scientist at Abbott Laboratories. Dr. Giordano earned a
Ph.D. in Molecular Genetics at Ohio State
University.
"I'm looking forward to the potential of building a leading drug
discovery and development platform in the non-opioid pain space and
pipeline of treatments that may someday positively affect the lives
of millions of people across the globe," Dr. Giordano
continued.
About JanOne
JanOne is a unique NASDAQ-listed company
offering innovative, actionable solutions that it believes can help
create an end to the opioid crisis. JanOne is dedicated to funding
resources toward innovation, technology, and education to find a
key resolution to the national opioid epidemic, which is one of the
deadliest and widespread in the country's history. The company
continues to operate its legacy businesses – ARCA Recycling and
GeoTraq – under their current brand names. JanOne's subsidiary ARCA
Recycling recycles household appliances by providing turnkey
recycling and replacement services for utilities and other sponsors
of energy efficiency programs. JanOne's subsidiary GeoTraq engages
in the development, design and, ultimately, expected sale of Mobile
IoT modules. Please visit www.janone.com for additional
information.
Contact: Michele Hart Henry;
1-302-463-6167
View original content to download
multimedia:http://www.prnewswire.com/news-releases/janone-names-tony-giordano-phd-as-chief-scientific-officer-300968049.html
SOURCE JanOne